Geddes A M, McGhie D, Ball A P, Gould I
Scand J Infect Dis Suppl. 1978(13):78-81.
We have studied cefuroxime, a new beta-lactamase resistant cephalosporin, and cefoxitin, the first cephamycin antibiotic, which is also resistant to many beta-lactamases. Both of these antibiotics have been shown to be microbiologically superior to the "first generation" cephalosporins, cefuroxime having notable activity against Haemophilus influenzae, and cefoxitin against Bacteroides fragilis. Neither antibiotic is absorbed from the gut but, following parenteral administration, serum, urine and bile concentrations are high. Clinical trials have been conducted on both cefoxitin and cefuroxime. The results of these have been satisfactory and untoward side-effects minimal. We suggest that cefoxitin will be particularly valuable in the management of abdominal sepsis and cefuroxime in infections caused by H. influenzae.
我们研究了新型耐β-内酰胺酶头孢菌素头孢呋辛，以及第一代头霉素类抗生素头孢西丁，后者同样对多种β-内酰胺酶具有抗性。这两种抗生素在微生物学上均已显示出优于“第一代”头孢菌素，头孢呋辛对流感嗜血杆菌具有显著活性，而头孢西丁对脆弱拟杆菌具有活性。这两种抗生素均不能从肠道吸收，但经胃肠外给药后，血清、尿液和胆汁中的浓度较高。已对头孢西丁和头孢呋辛进行了临床试验。试验结果令人满意，不良反应极少。我们认为，头孢西丁在腹部脓毒症的治疗中特别有价值，而头孢呋辛在由流感嗜血杆菌引起的感染治疗中很有价值。
